ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer — Stella

Home/Ovarian Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Ovarian Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Alexander B Olawaiye, MD

Collaborators

Pfizer, Zenith Epigenetics

Enrollment target

~33 participants

Started

April 2023

Primary completion

December 2031

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years and older

Sex

Female only

Last updated June 2025